A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/20/2011	WO2011128394A1 3-substituted 5-(pyrrolidine-1-carbonyl) pyrrolidine and its derivatives for use in the treatment of metabolic disorders
10/20/2011	WO2011128388A2 Oxazole and thiazole compounds as ksp inhibitors
10/20/2011	WO2011128381A1 Triazole compounds as ksp inhibitors
10/20/2011	WO2011128378A1 Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
10/20/2011	WO2011128364A1 Acetaminophen composition
10/20/2011	WO2011128336A1 Very low-dosed solid oral dosage forms for hrt
10/20/2011	WO2011128316A1 Azacyclic spiroderivatives as hsl inhibitors
10/20/2011	WO2011128301A1 Dithiin derivatives as fungicides
10/20/2011	WO2011128279A1 Arylethynyl derivatives
10/20/2011	WO2011128265A1 Aryl - /heteroaryl - cyclohexenyl - tetraazabenzo [e] azulenes as vasopressin antagonists
10/20/2011	WO2011128251A1 Novel 3,3-dimethyl tetrahydroquinoline derivatives
10/20/2011	WO2011128245A1 Homeopathic medicament comprising phenacetin for the treatment of cancer
10/20/2011	WO2011128230A1 Effervescent pharmaceutical compositions containing n-acetylcysteine
10/20/2011	WO2011128115A1 Analogues of etoposide for the treatment of tumours
10/20/2011	WO2011127948A1 Analogues of etoposide for the treatment of tumours
10/20/2011	WO2011127833A1 Benzoheterocyclic compounds, preparation methods and uses thereof
10/20/2011	WO2011127643A1 Pyridone derivatives
10/20/2011	WO2011127629A1 Pharmaceutical product of diphosphonate injection and preparation method thereof
10/20/2011	WO2011127586A1 Topical treatments for pain
10/20/2011	WO2011127567A1 Inhibitors of protein tyrosine kinase activity
10/20/2011	WO2011127565A1 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
10/20/2011	WO2011127538A1 Compound for treatment of respiratory condition or disease
10/20/2011	WO2011127537A1 Radiation sensitiser compositions
10/20/2011	WO2011127532A1 Tethered matrix metalloproteinase inhibitor
10/20/2011	WO2011127519A1 Combination treatment with vegf-c antagonists
10/20/2011	WO2011127499A1 Animal feed additive having an antimicrobial and growth-promoting effect
10/20/2011	WO2011103516A3 Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals
10/20/2011	WO2011101866A3 Gastric retention formulation containing baclofen
10/20/2011	WO2011101304A3 Piperidine derivatives
10/20/2011	WO2011098578A3 Liposome system for ocular administration
10/20/2011	WO2011098436A3 Progesterone receptor antagonists
10/20/2011	WO2011097273A8 Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine
10/20/2011	WO2011094546A3 Oligonucleotides which inhibit p53 induction in response to cellular stress
10/20/2011	WO2011093815A3 Pharmaceutical compositions comprising formoterol and mometasone
10/20/2011	WO2011092293A3 Cyclohexyl amide derivatives as crf receptor antagonists
10/20/2011	WO2011082273A3 Substituted pyrrolo-aminopyrimidine compounds
10/20/2011	WO2011082268A3 Substituted naphthalenyl-pyrimidine compounds
10/20/2011	WO2011080739A3 Synergistic antibiotic combinations and derivatives
10/20/2011	WO2011079230A3 Heterocyclic compounds as janus kinase inhibitors
10/20/2011	WO2011075210A3 Small molecules that covalently modify transthyretin
10/20/2011	WO2011072257A3 Amyloid binding agents
10/20/2011	WO2011072218A3 Stable formulations for lyophilizing therapeutic particles
10/20/2011	WO2011072181A3 Method of treating pancreatic cancer
10/20/2011	WO2011070318A3 Topical formulation
10/20/2011	WO2011069076A3 Sustained release donepezil formulations
10/20/2011	WO2011069063A3 Multicyclic compounds and methods of use thereof
10/20/2011	WO2011066980A3 Oral dosage forms with reduced potential for drug abuse
10/20/2011	WO2011066542A3 6-substituted estradiol derivatives and methods of use
10/20/2011	WO2011066417A3 Antibodies and conjugates for modulators of angiogenesis
10/20/2011	WO2011060887A8 Method for production of f-18 labeled glutamic acid derivatives
10/20/2011	WO2011060351A3 Coloring composition containing an aromatic compound and tyrosinase
10/20/2011	WO2011060049A3 Spiro-oxindole mdm2 antagonists
10/20/2011	WO2011059198A3 Pharmaceutical composition containing a bisphosphonate
10/20/2011	WO2011056978A3 S isomers of alpha-methyl hydrocinnamic acid for the treatment of blood disorders
10/20/2011	WO2011056871A3 Rhamnolipid mechanism
10/20/2011	WO2011055965A3 Methods for treating attention-deficit/hyperactivity disorder
10/20/2011	WO2011052940A3 Process for preparing clopidogrel hydrogensulfate form i
10/20/2011	WO2011052923A3 Novel 1,6-disubstituted indole compounds as protein kinase inhibitors
10/20/2011	WO2011047390A3 Heterocyclic benzoxazole compositions as inhibitors of hepatitis c virus
10/20/2011	WO2011047173A9 Pharmaceutical compositions for oral administration
10/20/2011	WO2011046905A3 Pharmaceutical compositions
10/20/2011	WO2011043519A3 Sulfonamide derivatives as serotonin receptor antagonist and serotonin reuptake inhibitor
10/20/2011	WO2011038210A3 Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
10/20/2011	WO2011038157A3 Zinc-containing compositions for the treatment of diseases, illnesses and syndromes associated with exposure to pore forming toxins
10/20/2011	WO2011036357A3 Stable, liquid, ready-to-use ketoprofen formulation
10/20/2011	WO2011034896A3 Small molecule inhibitors of the alpha4-paxillin interaction
10/20/2011	WO2011025862A3 Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1
10/20/2011	WO2011025230A9 Gaba release-regulating agent in cerebellum
10/20/2011	WO2011023304A3 Novel antiparasitic combination of active substances
10/20/2011	WO2011006504A3 Treatment of hyperproliferative conditions
10/20/2011	WO2010130393A3 Orodispersible tablet containing a vardenafil salt
10/20/2011	WO2010124874A9 Hepcidin binding nucleic acids
10/20/2011	WO2010117829A8 Differentially expressed micrornas as biomarkers for the diagnosis and treatment of sjögren's syndrome
10/20/2011	WO2006006152A3 Treatment of disorders and diseases of the colon
10/20/2011	US20110257586 Calciumphosphate-based nanoparticles as carrier-systems for photodynamic therapy
10/20/2011	US20110257583 Thiadiazole Compounds and Uses Thereof
10/20/2011	US20110257504 Biologically integrated electrode devices
10/20/2011	US20110257430 Novel cocrystallization
10/20/2011	US20110257407 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
10/20/2011	US20110257405 Process for producing crystal
10/20/2011	US20110257381 Pharmaceutical composition comprising chito-oligomers
10/20/2011	US20110257271 Derivatives of dimethylcurcumin
10/20/2011	US20110257270 Drug for treatment of colon cancer
10/20/2011	US20110257269 Preventive and/or therapeutic agent for inflammatory bowel diseases
10/20/2011	US20110257268 Reduction of Sterols and Other Compounds from Oils
10/20/2011	US20110257267 Reducing the Risk of Pathological Effects of Traumatic Brain Injury
10/20/2011	US20110257266 Therapeutic Regimen and Methods for Treating or Ameliorating Visual Disorders Associated
10/20/2011	US20110257264 Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis
10/20/2011	US20110257263 Jasmonic acid compounds in cocoa products
10/20/2011	US20110257262 Crystalline ingenol mebutate
10/20/2011	US20110257261 Platinum (iv) complexes for use in dual mode pharmaceutical therapy
10/20/2011	US20110257260 3,4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor
10/20/2011	US20110257259 Nut skin products and methods of use thereof
10/20/2011	US20110257258 Method for Preventing and Treating Avian Influenza in Human
10/20/2011	US20110257257 Composition for treatment of epithelial tissue
10/20/2011	US20110257256 Cannabinoids for use in treating or preventing cognitive impairment and dementia
10/20/2011	US20110257255 Composition and method for inhibition of nerve transmission
10/20/2011	US20110257254 Adamantane Derivatives Of Aza-Crown Ethers And Their Use In Treatment Of Tumor
10/20/2011	US20110257253 Preparation method of polymeric micellar nanoparticles composition containing a poorly water-soluble drug
10/20/2011	US20110257252 Novel antithrombotic diadenosine tetraphosphates and related analogs

1 ... 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 ... 7860